Edition:
United States

Deciphera Pharmaceuticals Inc (DCPH.OQ)

DCPH.OQ on NASDAQ Stock Exchange Global Select Market

25.31USD
25 May 2018
Change (% chg)

$0.26 (+1.04%)
Prev Close
$25.05
Open
$25.02
Day's High
$25.45
Day's Low
$24.83
Volume
24,462
Avg. Vol
43,564
52-wk High
$29.97
52-wk Low
$15.37

Chart for

About

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally... (more)

Overall

Beta: --
Market Cap(Mil.): $824.96
Shares Outstanding(Mil.): 32.59
Dividend: --
Yield (%): --

Financials

  DCPH.OQ Industry Sector
P/E (TTM): -- 238.69 33.30
EPS (TTM): -2.05 -- --
ROI: -60.13 -7.54 13.04
ROE: -729.94 -10.33 14.90

BRIEF-Deciphera Pharma Initiates Late Stage Study In Gastrointestinal Cancer Patients

* DECIPHERA PHARMACEUTICALS INITIATES PHASE 3 CLINICAL STUDY WITH DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (“INVICTUS” STUDY)

Jan 04 2018

BRIEF-Deciphera Pharmaceuticals Announces Orphan Drug Designation From The EMA For DCC-2618 For The Treatment Of Gastrointestinal Stromal Tumors

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES ORPHAN DRUG DESIGNATION FROM THE EMA FOR DCC-2618 FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS Source text for Eikon: Further company coverage:

Nov 28 2017

Earnings vs. Estimates